Somewhat Favorable Press Coverage Somewhat Unlikely to Affect BioMarin Pharmaceutical (BMRN) Stock Price
News articles about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.6282862491417 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- WORLDSymposium Recognizes BioMarin’s Brineura® (cerliponase alfa) with 2018 New Treatment Award (finance.yahoo.com)
- BioMarin Pharma (BMRN) Announced Interim Data of Phase 1/2 … – StreetInsider.com (streetinsider.com)
- BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium™ 2018 (finance.yahoo.com)
- Consensus Estimates and Trading Data for BioMarin Pharmaceutical Inc. (BMRN) – Market Movers (financialqz.com)
- BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Heffx Trading Review – Live Trading News (livetradingnews.com)
Several brokerages recently weighed in on BMRN. ValuEngine downgraded BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday. JPMorgan Chase & Co. decreased their price target on BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating for the company in a report on Wednesday, January 24th. BidaskClub downgraded BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $114.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, January 18th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $113.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $111.60.
In other news, EVP George Eric Davis sold 1,200 shares of the firm’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Henry J. Fuchs sold 15,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $89.23, for a total value of $1,338,450.00. The disclosure for this sale can be found here. Insiders sold 90,750 shares of company stock valued at $8,159,588 in the last quarter. 1.85% of the stock is currently owned by company insiders.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.